This registry-based study provides a comprehensive overview of global and mainland China MS drug clinical trials from 2004 to 2024. While global trial activity remained sustained over the past two decades, trial registrations in mainland China increased markedly in recent years, although the development structure differed from global patterns, with a higher proportion of BE studies and late-phase trials. These findings provide a reference for MS clinical drug development.
Chen et al. (Wed,) studied this question.